A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors

Trial Profile

A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs EC 1456 (Primary) ; Technetium Tc99m etarfolatide (Primary)
  • Indications Advanced breast cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Endocyte
  • Most Recent Events

    • 06 Jun 2017 Results (n=74) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 According to an Endocyte media release, the company is stopping enrollment in the phase Ib part of this trial because assessment in folate receptor-positive (FR-positive) disease across multiple cohorts of patients and multiple dosing schedules did not yield the level of clinical activity necessary to support continued advancement of this agent.
    • 02 Jun 2017 Status changed from recruiting to active, no longer recruiting according to an Endocyte media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top